These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 17366897)

  • 21. Association Between Activation of the Programmed Cell Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Pathway and Pain in Patients with Cancer.
    Zhang J; Zhang H; Luo Y
    Med Sci Monit; 2019 Feb; 25():1275-1282. PubMed ID: 30771277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.
    Okuma Y; Hosomi Y; Nakahara Y; Watanabe K; Sagawa Y; Homma S
    Lung Cancer; 2017 Feb; 104():1-6. PubMed ID: 28212990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy.
    Kim HJ; Park S; Kim KJ; Seong J
    Radiother Oncol; 2018 Oct; 129(1):130-135. PubMed ID: 29366520
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Dual-Channel Intelligent Point-of-Care Testing System for Soluble Programmed Death-1 and Programmed Death-Ligand 1 Detection Based on Folding Paper-Based Immunosensors.
    Xing Y; Liu J; Luo J; Ming T; Yang G; Sun S; Xu S; Li X; He E; Kong F; Yan S; Yang Y; Cai X
    ACS Sens; 2022 Feb; 7(2):584-592. PubMed ID: 35060694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased levels of soluble co-stimulatory molecule PD-L1 (B7-H1) in the plasma of viraemic HIV-1
    León-Flores A; Del Río Estrada PM; Álvarez-García LX; Piten-Isidro E; Reyes-Terán G
    Immunol Lett; 2018 Nov; 203():70-79. PubMed ID: 30236481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increase of Soluble Programmed Cell Death Ligand 1 in Patients with Chronic Hepatitis C.
    Yamagiwa S; Ishikawa T; Waguri N; Sugitani S; Kamimura K; Tsuchiya A; Takamura M; Kawai H; Terai S
    Int J Med Sci; 2017; 14(5):403-411. PubMed ID: 28539815
    [No Abstract]   [Full Text] [Related]  

  • 27. Specific intracellular binding peptide as sPD-L1 antibody mimic: Robust binding capacity and intracellular region specific modulation upon applied to sensing research.
    Hu J; Zhang ZH; Zhu Z; Chen J; Hu X; Chen H
    Biosens Bioelectron; 2021 Aug; 185():113269. PubMed ID: 33930752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effects of soluble programmed death ligand 1 on regulating the proliferation of T lymphocytes and its mechanism].
    Zhao J; Pan X; Xing Y; Lu M; Chen Y; Shi M
    Zhonghua Yi Xue Za Zhi; 2015 Feb; 95(6):449-52. PubMed ID: 25916783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Soluble PD-L1 improved direct ARDS by reducing monocyte-derived macrophages.
    Xu J; Wang J; Wang X; Tan R; Qi X; Liu Z; Qu H; Pan T; Zhan Q; Zuo Y; Yang W; Liu J
    Cell Death Dis; 2020 Oct; 11(10):934. PubMed ID: 33127884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased Soluble PD-L1 Levels in the Plasma of Patients with Epithelial Ovarian Cancer Correlate with Plasma Levels of
    Koukourakis MI; Kontomanolis E; Sotiropoulou M; Mitrakas A; Dafa E; Pouliliou S; Sivridis E; Giatromanolaki A
    Anticancer Res; 2018 Oct; 38(10):5739-5745. PubMed ID: 30275195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Selection of Chemotherapy Regimen on the Basis of Monitoring NLR and Soluble PD-L1 during CRC Chemotherapy].
    Muneoka K; Shirai Y; Sasaki M; Honma S; Sakata J; Kanda J; Wakabayashi H; Wakai T; Miyazaki M
    Gan To Kagaku Ryoho; 2018 Aug; 45(8):1159-1163. PubMed ID: 30158411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased Levels of Soluble Programmed Death Ligand 1 Associate with Malignancy in Patients with Dermatomyositis.
    Chen H; Peng Q; Yang H; Yin L; Shi J; Zhang Y; Wang G
    J Rheumatol; 2018 Jun; 45(6):835-840. PubMed ID: 29419471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The level of soluble programmed death-1 in peripheral blood of patients with lung cancer and its clinical implications].
    Xing YF; Zhang ZL; Shi MH; Ma Y; Chen YJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):102-6. PubMed ID: 22455965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of soluble programmed death-1 (sPD-1) and sPD-ligand 1 in patients with cystic echinococcosis.
    Li Y; Xiao Y; Su M; Zhang R; Ding J; Hao X; Ma Y
    Exp Ther Med; 2016 Jan; 11(1):251-256. PubMed ID: 26889250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors.
    Lin DY; Tanaka Y; Iwasaki M; Gittis AG; Su HP; Mikami B; Okazaki T; Honjo T; Minato N; Garboczi DN
    Proc Natl Acad Sci U S A; 2008 Feb; 105(8):3011-6. PubMed ID: 18287011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib.
    Sorensen SF; Demuth C; Weber B; Sorensen BS; Meldgaard P
    Lung Cancer; 2016 Oct; 100():77-84. PubMed ID: 27597284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells.
    Pen JJ; Keersmaecker BD; Heirman C; Corthals J; Liechtenstein T; Escors D; Thielemans K; Breckpot K
    Gene Ther; 2014 Mar; 21(3):262-71. PubMed ID: 24401835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased soluble programed cell death-ligand 1 is associated with acute coronary syndrome.
    Fujisue K; Yamamoto E; Sueta D; Takae M; Nishihara T; Komorita T; Usuku H; Yamanaga K; Ito M; Hoshiyama T; Kanazawa H; Takashio S; Arima Y; Araki S; Soejima H; Kaikita K; Matsushita K; Tsujita K
    Int J Cardiol; 2022 Feb; 349():1-6. PubMed ID: 34843822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Soluble PD-L1 and B7-H4 serum levels during the course of physiological pregnancy.
    Mach P; Köninger A; Reisch B; Kimmig R; Gellhaus A
    Am J Reprod Immunol; 2022 Mar; 87(3):e13519. PubMed ID: 34974633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors.
    Ando K; Hamada K; Watanabe M; Ohkuma R; Shida M; Onoue R; Kubota Y; Matsui H; Ishiguro T; Hirasawa Y; Ariizumi H; Tsurutani J; Yoshimura K; Tsunoda T; Kobayashi S; Wada S
    Anticancer Res; 2019 Sep; 39(9):5195-5201. PubMed ID: 31519633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.